Minerva Neurosciences Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Minerva Neurosciences wird ein Gewinn- und Umsatzwachstum von 44.2% bzw. 88% pro Jahr prognostiziert, während der Gewinn pro Aktie um 37.4% pro Jahr wachsen soll.

Wichtige Informationen

44.2%

Wachstumsrate der Gewinne

37.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.5%
Wachstumsrate der Einnahmen	88.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	06 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Minerva says FDA declined to accept marketing application for schizophrenia drug

Oct 17

Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Deliver On Growth Plans?

Jan 26

Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation

Oct 02

Minerva Neurosciences' (NASDAQ:NERV) Shareholders Are Down 59% On Their Shares

Mar 03

What You Need To Know About Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Investor Composition

Jan 27

We're Keeping An Eye On Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Rate

Dec 23

A Potential Trade Arises On Minerva

Dec 09

A Look At Minerva Neurosciences' (NASDAQ:NERV) Share Price Returns

Nov 18

Minerva Neurosciences EPS beats by $0.03

Nov 02

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:NERV - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-46	N/A	N/A	1
12/31/2025	N/A	-30	N/A	N/A	1
12/31/2024	N/A	-2	N/A	N/A	1
9/30/2024	N/A	-3	-20	-20	N/A
6/30/2024	N/A	-34	-21	-21	N/A
3/31/2024	N/A	-32	-21	-21	N/A
12/31/2023	N/A	-30	-15	-15	N/A
9/30/2023	N/A	-28	-13	-13	N/A
6/30/2023	N/A	-27	-18	-18	N/A
3/31/2023	N/A	-29	-19	-19	N/A
12/31/2022	N/A	-32	-25	-25	N/A
9/30/2022	N/A	-47	-25	-25	N/A
6/30/2022	N/A	-49	-24	-24	N/A
3/31/2022	N/A	-51	-25	-25	N/A
12/31/2021	N/A	-50	-25	-25	N/A
9/30/2021	N/A	-36	-27	-27	N/A
6/30/2021	N/A	-35	-28	-28	N/A
3/31/2021	41	5	-30	-30	N/A
12/31/2020	41	2	-34	-34	N/A
9/30/2020	41	-21	-41	-41	N/A
6/30/2020	41	-27	-40	-40	N/A
3/31/2020	N/A	-69	-43	-43	N/A
12/31/2019	N/A	-72	-43	-43	N/A
9/30/2019	N/A	-55	-39	-39	N/A
6/30/2019	N/A	-54	-40	-40	N/A
3/31/2019	N/A	-54	-41	-41	N/A
12/31/2018	N/A	-50	-42	-42	N/A
9/30/2018	N/A	-37	-41	-41	N/A
6/30/2018	N/A	-36	N/A	-6	N/A
3/31/2018	N/A	-33	N/A	-2	N/A
12/31/2017	N/A	-32	N/A	3	N/A
9/30/2017	N/A	-41	N/A	3	N/A
6/30/2017	N/A	-38	N/A	-26	N/A
3/31/2017	N/A	-34	N/A	-26	N/A
12/31/2016	N/A	-31	N/A	-26	N/A
9/30/2016	N/A	-30	N/A	-23	N/A
6/30/2016	N/A	-28	N/A	-24	N/A
3/31/2016	N/A	-29	N/A	-25	N/A
12/31/2015	N/A	-27	N/A	-24	N/A
9/30/2015	N/A	-26	N/A	-23	N/A
6/30/2015	N/A	-47	N/A	-44	N/A
3/31/2015	N/A	-60	N/A	-40	N/A
12/31/2014	N/A	-57	N/A	-36	N/A
9/30/2014	N/A	-52	N/A	-32	N/A
6/30/2014	N/A	-25	N/A	-5	N/A
3/31/2014	N/A	-6	N/A	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: NERV wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: NERV wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: NERV wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: NERV wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: NERV wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von NERV in 3 Jahren voraussichtlich hoch sein wird

Minerva Neurosciences Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased to US$6.67

Price target increased to US$8.33

Consensus revenue estimates fall to US$400.0k

Consensus forecasts updated

Analysts update estimates

Recent updates

Minerva Neurosciences, Inc., Annual General Meeting, Dec 05, 2024

Minerva Neurosciences Receives Second Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed Securities Requirement under Nasdaq Listing Rule 5550(b)(2)

Minerva Neurosciences Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed Securities Requirement Nasdaq's Listing Rule 5550(b)(2)

Minerva Neurosciences, Inc., Annual General Meeting, Sep 27, 2023

Minerva Neurosciences, Inc. announced that it expects to receive $19.999994 million in funding from Frazier Healthcare Partners, Boehringer Ingelheim International GmbH

Nasdaq Determines to Delist Minerva Neurosciences' Securities from The Nasdaq Capital Market

Minerva Neurosciences, Inc. to Report Q1, 2023 Results on May 15, 2023

Minerva Neurosciences, Inc. Announces Board Changes

Minerva Neurosciences, Inc. Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Minerva Neurosciences Receives Non-Compliance Notice from The Nasdaq Stock Market LLC

Minerva Neurosciences, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Minerva Neurosciences, Inc. Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Minerva says FDA declined to accept marketing application for schizophrenia drug

Minerva Neurosciences: Biotech On The Move

Minerva Neurosciences, Inc. Submits New Drug Application to Fda for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

Minerva stock rises on filing for FDA approval of schizophrenia therapy

We're Hopeful That Minerva Neurosciences (NASDAQ:NERV) Will Use Its Cash Wisely

Insufficient new directors

Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Price target decreased to US$6.67

Minerva Neurosciences, Inc. Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin

Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Deliver On Growth Plans?

Price target increased to US$8.33

Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation

Consensus revenue estimates fall to US$400.0k

Minerva Neurosciences, Inc.(NasdaqGM:NERV) dropped from Russell 3000E Growth Index

Investor sentiment improved over the past week

Consensus forecasts updated

Minerva Neurosciences, Inc. Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension

Investor sentiment deteriorated over the past week

Analysts update estimates

Earnings beat expectations, revenue disappoints

Minerva Neurosciences' (NASDAQ:NERV) Shareholders Are Down 59% On Their Shares

Minerva Neurosciences, Inc. to Report Q4, 2020 Results on Mar 08, 2021

What You Need To Know About Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Investor Composition

Bernstein Liebhard LLP Reminds Investors in SPLK, NAK, and NERV of Filing Deadlines

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Minerva Neurosciences, Inc

We're Keeping An Eye On Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Rate

New 90-day low: US$2.58

Block & Leviton LLP Announces That It Has Filed A Lawsuit Against Minerva Neurosciences, Inc. for Securities Fraud

A Potential Trade Arises On Minerva

A Look At Minerva Neurosciences' (NASDAQ:NERV) Share Price Returns

New 90-day high: US$3.59

Earnings miss expectations

Minerva Neurosciences EPS beats by $0.03

Minerva Neurosciences, Inc. to Report Q3, 2020 Results on Nov 02, 2020

New 90-day low - US$3.21

Minerva Neurosciences, Inc.(NasdaqGM:NERV) dropped from Russell Microcap Value Index

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken